News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280,213 Results
Type
Article (14837)
Company Profile (300)
Press Release (265071)
Multimedia
Podcasts (72)
Webinars (11)
Section
Business (79808)
Career Advice (159)
Deals (13320)
Drug Delivery (38)
Drug Development (50673)
Employer Resources (31)
FDA (5824)
Job Trends (5166)
News (145022)
Policy (10069)
Tag
Academia (920)
Accelerated approval (18)
Adcomms (14)
Allergies (76)
Alliances (21775)
ALS (119)
Alzheimer's disease (1018)
Antibody-drug conjugate (ADC) (217)
Approvals (6003)
Artificial intelligence (235)
Autoimmune disease (97)
Automation (9)
Bankruptcy (105)
Best Places to Work (4562)
BIOSECURE Act (6)
Biosimilars (98)
Biotechnology (230)
Bladder cancer (95)
Brain cancer (42)
Breast cancer (324)
Cancer (2953)
Cardiovascular disease (225)
Career advice (145)
Career pathing (6)
CAR-T (210)
CDC (5)
Cell therapy (541)
Cervical cancer (14)
Clinical research (43416)
Collaboration (1035)
Company closure (2)
Compensation (552)
Complete response letters (36)
COVID-19 (1094)
CRISPR (81)
C-suite (487)
Cystic fibrosis (108)
Data (4097)
Denatured (13)
Depression (81)
Diabetes (244)
Diagnostics (1365)
Digital health (9)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (173)
Drug pricing (42)
Drug shortages (3)
Duchenne muscular dystrophy (202)
Earnings (31544)
Editorial (23)
Employer branding (4)
Employer resources (29)
Events (51408)
Executive appointments (608)
FDA (7436)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (20)
Funding (911)
Gene editing (169)
Generative AI (18)
Gene therapy (458)
GLP-1 (488)
Government (1139)
Grass and pollen (3)
Guidances (162)
Healthcare (6607)
HIV (15)
Huntington's disease (39)
IgA nephropathy (70)
Immunology and inflammation (178)
Immuno-oncology (27)
Indications (51)
Infectious disease (1193)
Inflammatory bowel disease (150)
Inflation Reduction Act (10)
Influenza (36)
Intellectual property (154)
Interviews (18)
IPO (7333)
IRA (12)
Job creations (868)
Job search strategy (129)
Kidney cancer (9)
Labor market (22)
Layoffs (241)
Leadership (9)
Legal (1402)
Liver cancer (39)
Longevity (9)
Lung cancer (405)
Lymphoma (241)
Machine learning (21)
Management (7)
Manufacturing (339)
MASH (127)
Medical device (2660)
Medtech (2667)
Mergers & acquisitions (6561)
Metabolic disorders (683)
Multiple sclerosis (93)
NASH (13)
Neurodegenerative disease (208)
Neuropsychiatric disorders (64)
Neuroscience (1866)
NextGen: Class of 2025 (2030)
Non-profit (864)
Now hiring (28)
Obesity (306)
Opinion (122)
Ovarian cancer (123)
Pain (91)
Pancreatic cancer (144)
Parkinson's disease (213)
Partnered (12)
Patents (281)
Patient recruitment (292)
Peanut (42)
People (26515)
Pharmaceutical (45)
Pharmacy benefit managers (6)
Phase I (15376)
Phase II (20174)
Phase III (12753)
Pipeline (2657)
Policy (86)
Postmarket research (853)
Preclinical (6519)
Press Release (30)
Prostate cancer (137)
Psychedelics (48)
Radiopharmaceuticals (232)
Rare diseases (582)
Real estate (1446)
Recruiting (12)
Regulatory (9708)
Reports (19)
Research institute (969)
Resumes & cover letters (18)
Rett syndrome (21)
RNA editing (16)
RSV (16)
Schizophrenia (116)
Series A (169)
Series B (121)
Service/supplier (1)
Sickle cell disease (75)
Special edition (18)
Spinal muscular atrophy (118)
Sponsored (15)
Startups (2000)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (17)
The Weekly (58)
Vaccines (319)
Venture capital (58)
Weight loss (164)
Women's health (23)
Worklife (2)
Date
Today (111)
Last 7 days (213)
Last 30 days (1133)
Last 365 days (18171)
2026 (207)
2025 (18096)
2024 (20548)
2023 (22418)
2022 (26830)
2021 (27815)
2020 (23359)
2019 (16228)
2018 (11740)
2017 (13750)
2016 (11846)
2015 (14355)
2014 (10394)
2013 (7487)
2012 (7533)
2011 (7615)
2010 (7437)
Location
Africa (155)
Alabama (63)
Alaska (2)
Arizona (66)
Arkansas (5)
Asia (18156)
Australia (3086)
California (6726)
Canada (1777)
China (719)
Colorado (233)
Connecticut (238)
Delaware (223)
Europe (38946)
Florida (846)
Georgia (203)
Hawaii (2)
Idaho (17)
Illinois (372)
India (31)
Indiana (151)
Iowa (8)
Japan (204)
Kansas (79)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (712)
Massachusetts (5329)
Michigan (103)
Minnesota (238)
Mississippi (3)
Missouri (31)
Montana (15)
Nebraska (5)
Nevada (29)
New Hampshire (18)
New Jersey (1572)
New Mexico (12)
New York (1680)
North Carolina (793)
North Dakota (6)
Northern California (3268)
Ohio (173)
Oklahoma (11)
Oregon (23)
Pennsylvania (1217)
Puerto Rico (8)
Rhode Island (25)
South America (211)
South Carolina (9)
Southern California (2658)
Tennessee (38)
Texas (868)
United States (22250)
Utah (92)
Virginia (130)
Washington D.C. (36)
Washington State (561)
West Virginia (1)
Wisconsin (37)
280,213 Results for "scorpion therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
·
2 min read
·
Dan Samorodnitsky
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.
November 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
January 14, 2025
·
6 min read
Business
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.
October 24, 2023
·
3 min read
Press Releases
Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478
December 10, 2024
·
6 min read
Business
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.
January 4, 2024
·
7 min read
Drug Development
Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
Scorpion Therapeutics, Inc announced preclinical data for STX-241, an orally bioavailable, highly selective, central nervous system -penetrant and potentially best-in-class fourth generation epidermal growth factor receptor tyrosine kinase inhibitor designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation in non-small cell lung cancer.
October 13, 2023
·
7 min read
Business
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer
Scorpion Therapeutics, Inc. (“Scorpion”) today announced an exclusive collaboration and license agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor (“EGFR”) inhibitors.
April 4, 2023
·
8 min read
Genetown
Scorpion Therapeutics to Present at Jefferies Healthcare Conference
Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in New York City.
June 3, 2022
·
1 min read
Business
Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer
Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine, today announced the appointment of Michael Streit, M.D., M.B.A as the Company’s first Chief Medical Officer (“CMO”).
September 12, 2022
·
3 min read
1 of 28,022
Next